Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses...